111 related articles for article (PubMed ID: 9118458)
1. Response of sensitive and resistant IgM immunocytomas to cis-diamminedichloroplatinum (II) does not correlate with the platination level or with the formation or removal of DNA adducts.
Vendrik CP; Fichtinger-Schepman AM; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; de Groot G; Berends GF; Steerenberg PA
Cancer Chemother Pharmacol; 1997; 39(6):479-85. PubMed ID: 9118458
[TBL] [Abstract][Full Text] [Related]
2. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.
Fichtinger-Schepman AM; Vendrik CP; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; Claessen AM; van der Velde-Visser SD; de Groot G; Wubs KL; Steerenberg PA
Cancer Res; 1989 Jun; 49(11):2862-7. PubMed ID: 2720647
[TBL] [Abstract][Full Text] [Related]
3. The formation and persistence of carboplatin-DNA adducts in rats.
Blommaert FA; Michael C; van Dijk-Knijnenburg HC; Schornagel JH; den Engelse L; Fichtinger-Schepman AM
Cancer Chemother Pharmacol; 1996; 38(3):273-80. PubMed ID: 8646803
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
5. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
[TBL] [Abstract][Full Text] [Related]
6. Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs.
Vendrik CP; de Jong WH; Van der Minnen AC; Fichtinger-Schepman AM; Steerenberg PA; Schornagel JH
Anticancer Res; 1990; 10(2A):447-52. PubMed ID: 2346318
[TBL] [Abstract][Full Text] [Related]
7. Iododeoxyuridine chemosensitization of cis-diamminedichloroplatinum(II) in human bladder cancer cells.
Chi KH; Kunugi KA; Kinsella TJ
Cancer Res; 1994 May; 54(10):2701-6. PubMed ID: 8168100
[TBL] [Abstract][Full Text] [Related]
8. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
9. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
[TBL] [Abstract][Full Text] [Related]
10. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
Hospers GA; Mulder NH; de Jong B; de Ley L; Uges DR; Fichtinger-Schepman AM; Scheper RJ; de Vries EG
Cancer Res; 1988 Dec; 48(23):6803-7. PubMed ID: 2846161
[TBL] [Abstract][Full Text] [Related]
13. cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats.
Reed E; Litterst CL; Thill CC; Yuspa SH; Poirier MC
Cancer Res; 1987 Feb; 47(3):718-22. PubMed ID: 3802077
[TBL] [Abstract][Full Text] [Related]
14. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
15. Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNA.
Los G; van Vugt MJ; den Engelse L; Pinedo HM
Biochem Pharmacol; 1993 Oct; 46(7):1229-37. PubMed ID: 8216374
[TBL] [Abstract][Full Text] [Related]
16. The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.
Hospers GA; de Vries EG; Mulder NH
Br J Cancer; 1990 Jan; 61(1):79-82. PubMed ID: 2153398
[TBL] [Abstract][Full Text] [Related]
17. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in cervix carcinoma HeLa cells: relation to DNA repair.
Chao CC
Mol Pharmacol; 1994 Jun; 45(6):1137-44. PubMed ID: 8022407
[TBL] [Abstract][Full Text] [Related]
18. Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro.
Oldenburg J; Begg AC; van Vugt MJ; Ruevekamp M; Schornagel JH; Pinedo HM; Los G
Cancer Res; 1994 Jan; 54(2):487-93. PubMed ID: 8275486
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
[TBL] [Abstract][Full Text] [Related]
20. Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts.
De Pooter CM; Van Oosterom AT; Scalliet PG; Maes RA; de Bruijn EA
Biochem Pharmacol; 1996 Mar; 51(5):629-34. PubMed ID: 8615899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
